Abstract 1449P
Background
PRO-based symptom scores are routinely employed in time to deterioration (TTD) analyses. In contrast to PFS, the recurrent nature of PRO symptom deterioration may result in endpoints with “transient” terminal event times. The TTD framework forces a single-event solution onto a recurrent event problem. Recurrent event survival models remedy this limitation. Thus, we present a joint survival model (JM) linking recurrent PRO-based deterioration to PFS assessed by investigator (progression or death).
Methods
RATIONALE-305 (NCT03777657) was a randomized phase 3 trial of tislelizumab (TIS) + chemotherapy (chemo) vs. placebo (PBO) + chemo as first-line treatment for patients (pts) with locally advanced, unresectable, or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma. EORTC QLQ-C30 and QLQ-STO22 symptom endpoints were modeled. Osoba’s 10pt threshold was used to define PRO-based deterioration events from treatment cycles 2 to 38. Emphasis in abstract is placed on recurrent UGI deterioration (R UGI-D) events modeled with frailty cox models and PFS modeled via Cox proportional hazards models within a JM. The PFS model adjusted the R UGI-D model for informative missing PRO data. R UGI-D frailties predicted PFS. Pts were censored without R UGI-D events by Cycle 38 or time of disease progression or if they remained progression free to end of study.
Results
Of the 896 pts, 514 (57.4%), 254 (28.3%), 83 (9.3%), 26 (2.9%), 16 (1.8%), and 3 (0.3%) experienced zero (censored), one, two, three, four, and five R UGI-D events, respectively. Higher rates of R UGI-D events predicted increased risk of progression/death (HR 3.38, P<0.00001), irrespective of treatment. In contrast to PBO + chemo, TIS + chemo was not associated with significantly increased risk of R UGI-D events but was associated with a 27% reduction in risk of progression/death (HR 0.73, P=0.007). Similar findings were observed between recurrent deterioration in appetite, fatigue, and pain/discomfort and PFS.
Conclusions
This analysis demonstrated that recurrent PRO deterioration was strongly predictive of PFS in pts with advanced gastric/GEJ cancer.
Clinical trial identification
NCT03777657.
Editorial acknowledgement
Medical writing support, under the direction of the authors, was provided by Jason C. Allaire, PhD of Generativity Solutions Group. Editorial and submission support was provided by Envision Pharma Inc.
Legal entity responsible for the study
BeiGene, Ltd.
Funding
BeiGene, Ltd.
Disclosure
M. Moehler: Financial Interests, Personal, Speaker, Consultant, Advisor: Bayer, MSD, Merck Serono, Amgen, Taiho Pharmaceutical, Pfizer, Roche, Lilly, Servier, BeiGene, BMS, AstraZeneca, Astellas, Dragonfly, Novartis; Non-Financial Interests, Personal, Non remunerated activity: Amgen, Roche/Genentech, Merck Serono, MSD Oncology, BMS, AstraZeneca/MedImmune, Servier, Pierre Fabre, Sanofi, Falk Foundation, Transcenta, Daiichi Sankyo, Astellas, Nordic; Financial Interests, Personal, Research Grant: Amgen, Leap Therapeutics, Merck Serono, MSD. D. Serrano: Financial Interests, Personal, Research Funding: AbbVie, Alcon, BeiGene, BioMarin, Boehringer Ingelheim, Insmed, Janssen, Sanofi, Scilex, Seagen. H. Xu, T. Sheng, B. Barnes: Financial Interests, Personal, Full or part-time Employment: BeiGene. L. Li: Financial Interests, Personal, Full or part-time Employment: BeiGene; Financial Interests, Personal, Stocks/Shares: BeiGene; Financial Interests, Personal, Other, Travel: BeiGene. G. Barnes: Financial Interests, Personal, Full or part-time Employment: BeiGene; Financial Interests, Personal, Stocks/Shares: BeiGene. D. Oh: Financial Interests, Personal, Advisory Board: AstraZeneca, Novartis, Genentech/Roche, Merck Serono, Bayer, Taiho, Aslan, Halozyme, Zymeworks, BMS/Celgene, BeiGene, Basilea, Turning Point, Yuhan, Arcus Biosciences, IQVIA, MSD, LG Chem, Astellas, AbbVie, J-Pharma, Mirati Therapeutics, Eutilex, Moderna, Idience; Financial Interests, Institutional, Research Grant: AstraZeneca, Novartis, Array, Eli Lilly, Servier, BeiGene, MSD, Handok.
Resources from the same session
1515P - Surgery versus chemotherapy for pulmonary oligometastasis after pancreatectomy: A multicentre observational study
Presenter: Ryoji Takada
Session: Poster session 18
1516P - Lung-only metastatic PDAC: Another disease?
Presenter: Léa Mercier
Session: Poster session 18
1517P - Isolated LUng Metastases in pancreatic AdenoCArcinoma patients in a multicenter Italian cohort: The LU.M.A.CA study
Presenter: Giulia Orsi
Session: Poster session 18
1518P - Stereotactic radiotherapy and IMM-101 in patients with oligometastatic pancreatic cancer following FOLFIRINOX: The MEPANC trial
Presenter: Leonoor Wismans
Session: Poster session 18
Resources:
Abstract
1519P - Real-world evidence on long-term survivors of metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with liposomal irinotecan: NALLONG study
Presenter: Makoto Ueno
Session: Poster session 18
1520P - Real-world assessment of NALIRIFOX for advanced pancreatic ductal adenocarcinoma: An exploratory analysis
Presenter: Andreas Reichinger
Session: Poster session 18
Resources:
Abstract
1521P - Efficacy and safety of liposomal irinotecan plus S-1 in patients with metastatic pancreatic cancer after failure of first-line gemcitabine-based chemotherapy: Result of a phase I/II study
Presenter: Hiroshi Imaoka
Session: Poster session 18
1522P - S-1 monotherapy versus nanoliposomal irinotecan plus 5-fluorouracil/leucovorin regimen for second-line therapy of recurrent or metastatic pancreatic cancer (JON 2109-P)
Presenter: Yuichiro Tozuka
Session: Poster session 18
1523P - Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
Presenter: Yasin Sezgin
Session: Poster session 18